Physician profile
Federico Maese
NPI 1922123728
$3,224.99
in general payments reported to CMS, 2019-2025
15 companies · $827 in 2025
The $827 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $174 · 2021: $315 · 2022: $767 · 2023: $383 · 2024: $384 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.52 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,030.59 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $895.83 | 2019-2025 | Farxiga |
| Bridgebio Pharma, INC. | $337.78 | 2025 | Attruby |
| Siemens Medical Solutions USA, INC. | $220.59 | 2023-2024 | Cios Spin, Biograph Horizon-3r |
| Antares Pharma, INC. | $218.44 | 2022-2025 | Xyosted |
| Amgen INC. | $156.15 | 2024 | Krystexxa |
| Abbvie INC. | $101.49 | 2021-2023 | |
| Philips North America LLC | $80.55 | 2020-2024 | (Ck4) Mcot |
| Edwards Lifesciences Corporation | $62.94 | 2025 | Sapien 3 Ultra Resilia |
| Lilly USA, LLC | $40.08 | 2025 | Jardiance, Zepbound, Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.78 | 2022 | |
| Glaxosmithkline, LLC. | $18.27 | 2025 | Trelegy Ellipta |
| Paratek Pharmaceuticals, INC. | $14.43 | 2025 | Nuzyra |
| Globus Medical, INC. | $13.65 | 2025 | Senza |
| Ascensia Diabetes Care US INC. | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Federico Maese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.